By: Adam Feuerstein | 06/02/14 - 11:23 AM EDT
My Tweeted photo of the Northwest Biotherapeutics (NWBO) exhibition booth at the American Society of Clinical Oncology (ASCO) annual meeting doesn't do justice to its enormity.
$NWBO will dilute shareholders soon to pay for gigantic ASCO14 booth. Linda blew the budget! pic.twitter.com/4pafcG99ca Adam Feuerstein (@adamfeuerstein) May 31, 2014I'm sure Northwest Bio thought it would raise its profile with a booth the size of a small Illinois town, but from an investors' perspective, the company was simply the brunt of guffaws over the weekend for wasting a ridiculous amount of money.
As expected, there was no human response data on Northwest Bio's DC-Vax Direct poster on Sunday. I did get a chance to speak with MD Anderson Dr. Vivek Subbiah about the ongoing study. I asked him if he endorsed the company's reporting of anecdotal tumor shrinkage data. With Northwest execs hovering around us, Subbiah was careful to say the only results which matter will be those reported when the DC-Vax Direct study completes. Subbiah will not be reporting data on patient tumor response while the study is underway, although the company is free to do so, he said.
Keep that in mind when you read the next on-the-fly report from the DC-Vax Direct study issued in a Northwest Bio press release.
Northwest Bio shares are down 6% to $5.61 in Monday trading.
08/26/14 - 07:00 AM EDT
08/25/14 - 08:48 AM EDT
08/21/14 - 10:23 AM EDT
08/14/14 - 10:20 AM EDT
08/13/14 - 12:04 PM EDT
08/27/14 - 11:32 AM EDT
08/26/14 - 14:30 PM EDT
08/26/14 - 11:34 AM EDT
08/25/14 - 11:41 AM EDT
08/25/14 - 11:09 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.